Takeda Pharmaceutical (TAK) Competitors

Takeda Pharmaceutical (NYSE:TAK) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, earnings, analyst recommendations, dividends and valuation.

Does the media refer more to TAK or SNY?

In the previous week, Sanofi had 34 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 38 mentions for Sanofi and 4 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 1.29 beat Sanofi's score of 0.77 indicating that Takeda Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sanofi	14 Very Positive mention(s)	5 Positive mention(s)	10 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has higher valuation & earnings, TAK or SNY?

Sanofi has lower revenue, but higher earnings than Takeda Pharmaceutical. Sanofi is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$4.58T	0.01	$712.33M	$0.22	66.89
Sanofi	$44.46B	2.68	$6.02B	$2.80	17.33

Is TAK or SNY more profitable?

Sanofi has a net margin of 14.56% compared to Takeda Pharmaceutical's net margin of 2.36%. Sanofi's return on equity of 17.15% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	2.36%	10.64%	5.14%
Sanofi	14.56%	17.15%	9.80%

Do institutionals and insiders believe in TAK or SNY?

9.2% of Takeda Pharmaceutical shares are owned by institutional investors. Comparatively, 14.0% of Sanofi shares are owned by institutional investors. 0.0% of Takeda Pharmaceutical shares are owned by insiders. Comparatively, 1.0% of Sanofi shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Is TAK or SNY a better dividend stock?

Takeda Pharmaceutical pays an annual dividend of $0.55 per share and has a dividend yield of 3.7%. Sanofi pays an annual dividend of $1.60 per share and has a dividend yield of 3.3%. Takeda Pharmaceutical pays out 250.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Sanofi pays out 57.1% of its earnings in the form of a dividend.

Which has more risk and volatility, TAK or SNY?

Takeda Pharmaceutical has a beta of 0.23, meaning that its share price is 77% less volatile than the S&P 500. Comparatively, Sanofi has a beta of 0.48, meaning that its share price is 52% less volatile than the S&P 500.

Do analysts recommend TAK or SNY?

Sanofi has a consensus target price of $61.50, indicating a potential upside of 26.75%. Given Sanofi's stronger consensus rating and higher probable upside, analysts clearly believe Sanofi is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Sanofi	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.11

Summary

Sanofi beats Takeda Pharmaceutical on 15 of the 19 factors compared between the two stocks.